Lupin is currently trading at Rs. 1477.25, up by 10.95 points or 0.75% from its previous closing of Rs 1466.30 on the BSE.
The scrip opened at Rs. 1469.95 and has touched a high and low of Rs 1481.40 and Rs 1469.95 respectively. So far 17,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1911.55 on 09-Feb-2016 and a 52 week low of Rs 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs 1481.40 and Rs 1399.00 respectively. The current market cap of the company is Rs 66,677.00 crore.
The promoters holding in the company stood at 46.74%, while Institutions and Non-Institutions held 41.85% and 11.41% respectively.
Pharma Major Lupin has received tentative approval for its Balasalazide Disodium Tablets, 1.1 gm from the United States Food and Drug Administration (USFDA) to market a generic version of Salix Pharmaceuticals Inc's Giazo Tablets, 1.1 gm. The filing is from company's Goa manufacturing facility.
The company’s Balasalazide Disodium tablets 1.1 gm are the AB rated generic equivalent of Salix Pharmaceuticals Inc's Giazo Tablets, 1.1 gm. Balasalazide Disodium tablets are indicated for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older. Giazo Tablets had US sales of $0.79 million as per IMS MAT September 2016.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: